FDA Delays Approval of Donanemab for the Treatment of Early-Stage Alzheimer’s

The maker of donanemab, Eli Lilly, announced today that the Food and Drug Administration (FDA) will convene an advisory committee to consider the drug’s safety and efficacy, further delaying approval of the promising drug. UsAgainstAlzheimer’s issued the following statement in response.

Organizations Unite to Improve Brain Health

UsAgainstAlzheimer’s Launches Business Collaborative for Brain Health with founding partners AARP, GN Group, Eli Lilly, and Novo Nordisk, to improve brain health in the workforce.

Join US today

Become a Member of UsAgainstAlzheimer's and join a movement of people who don’t just talk about the Alzheimer’s crisis, but boldly step forward to become part of the solution. Defeating Alzheimer’s will take all of US. With your help, we can create a world where brain span matches lifespan.

Alz Stories Video Series

Open configuration options Alzheimer’s is a complex disease that impacts the lives of millions of Americans, often in very different ways. Learn more about the Alzheimer’s journey from people who are living it firsthand. Then, find out how to take charge of your own brain health and what UsAgainstAlzheimer’s is doing to promote prevention, early detection, and access to treatments for the nation’s sixth leading cause of death.

UsAgainstAlzheimer’s: Power of Us

Get to know UsAgainstAlzheimer’s, what we’ve accomplished, and where we’re headed through our powerful video introduction.

Say Hello to BrainGuide

Our platform BrainGuide™ empowers people of all ages and communities to understand and take action on brain health and Alzheimer's disease.

FDA Delays Approval of Donanemab for the Treatment of Early-Stage Alzheimer’s

Organizations Unite to Improve Brain Health

Join US today

Alz Stories Video Series

UsAgainstAlzheimer’s: Power of Us

Say Hello to BrainGuide

UsAgainstAlzheimer’s is engaged in a relentless pursuit to end Alzheimer’s, the sixth leading killer in America. Our work centers on prevention, early detection and diagnosis, and access to treatments – all regardless of gender, race, or ethnicity. To achieve our mission, we give voice to patients and caregivers while partnering with government, scientists, the private sector, and allied organizations -- the people who put the “Us” in UsAgainstAlzheimer’s.

Prevention

Alzheimer’s is not a normal part of aging. There are things we can all do to reduce our risk, like eating a healthy diet, exercising, and getting good sleep. People need to know what’s good for the body is good for the brain. Learn more about our prevention work and how you can take charge of your brain health.

CLICK HERE FOR MORE INFO

Early Detection & Diagnosis

Early detection and diagnosis give people a better chance of managing the disease. On top of that, current treatments are most effective with patients in the early stages of dementia.

Find out how we are raising awareness of the importance of early detection and how BrainGuide is helping people concerned about their brain health start a conversation with their doctor.

CLICK HERE FOR MORE INFO

Access to Treatments

We are working on multiple fronts to get safe and effective treatments into the hands of people who need them most. That includes working to ensure Alzheimer’s patients are treated fairly as the federal government considers drug approval and Medicare coverage for treatments.

See how else UsAgainstAlzheimer’s is fighting for access to treatments.

CLICK HERE FOR MORE INFO

 

Center for Brain Health Equity

Most Alzheimer’s patients are women, Latinos, and Black people. As a patient-centered organization, all our work is done with equity in mind, so we are addressing needs of the people who are most heavily impacted by the disease. Learn more about how UsAgainstAlzheimer’s Center for Brain Health Equity is working toward a healthcare system that works for everyone.

Recent News and Blog Posts

  • March 08, 2024

    FDA Delays Approval of Donanemab for the Treatment of Early-Stage Alzheimer’s

    Agency to convene an advisory committee to consider the drug.

     

    Read more
  • February 08, 2024

    Organizations Unite to Improve Brain Health

    UsAgainstAlzheimer’s Launches Business Collaborative for Brain Health with founding partners AARP, GN...

    Read more
  • February 06, 2024

    UsAgainstAlzheimer’s Statement on Discontinuation of Aduhelm

    George Vradenburg, chair and co-founder of UsAgainstAlzheimer’s, issued the following statement following...

    Read more
  • December 01, 2023

    UsAgainstAlzheimer’s Statement on the Passing of Justice Sandra Day O’Connor

    George Vradenburg, chair and co-founder of UsAgainstAlzheimer’s, issued the following statement following...

    Read more
  • Statement on Retirement of U.S. Representative Anna Eshoo

    UsAgainstAlzheimer’s chair and co-founder George Vradenburg issued the following statement in response...
    Read more
  • Applications for CMS GUIDE Model Being Accepted Through 1/30/24

    Medicare Part B doctors and health systems are encouraged to apply ASAP
    Read more

Reports

  • Resources
    alist 2023

    A-LIST Pulse of the Community – July 2023

  • Resources

    A-LIST Pulse of the Community – November 2022

  • Resources
    Us Against Alzheimer's 2021 Annual Report

    2021 Annual Report

    With breakthroughs in treatment, a remarkable step forward in prevention, and a new initiative to raise public awareness of the importance of brain health, many efforts were led by UsAgainstAlzheimer’s...